HomeREGULATORY
REGULATORY

MHLW Advisory Panel Backs Otsuka’s Schizophrenia Med Brexpiprazole and More
(Dec.5.2017)

A key advisory committee of the Ministry of Health, Labor and Welfare (MHLW) on December 4 supported approval for Otsuka Pharmaceutical’s atypical antipsychotic agent brexpiprazole, a hoped-to-be successor to the company’s bread-and-butter Abilify (aripiprazole) ...
(LOG IN FOR FULL STORY)